FlandersBio on Twitter

Follow us on Twitter

Archive for September 2013 - News

Archive for September 2013 - Nieuws

in het nederlands in english

FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.

FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.

Multiplicom launches three new mutation detection kits to enable the implementation of personalized cancer treatment

30.09.2013

Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing (MPS), today announces that it is launching three new somatic mutation detection kits which will enable users to implement personalized cancer treatment at an unprecedented level. read more

ThromboGenics Establishes Level 1 ADR Program for US Investors

30.09.2013

ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that it has established a sponsored Level 1 American Depositary Receipt (ADR) program. Trading of the ADRs commences today on the US over the counter (OTC) market under the ticker TBGNY. read more

Biogazelle serves as reference laboratory for Bio-Rad's droplet digital PCR system

27.09.2013

Biogazelle today annouced that it is serving is a reference laboratory for Bio-Rad’s QX200™ Digital Droplet PCR™ system (ddPCR) in Europe. This extends Biogazelle’s and Bio-Rad’s long-term partnership for PCR-based solutions. As a reference laboratory, Biogazelle uses ddPCR in its R&D programs and shares its ddPCR user experience with the PCR community. In addition, Biogazelle is acting as a ddPCR service provider for third parties who are interested in outsourcing a study. In addition, the Biogazelle laboratory also serves as a live research environment for prospective QX200 system customers. read more

ABLYNX AND MERCK SERONO FURTHER STRENGTHEN THEIR COLLABORATION ON CO-DISCOVERY AND CO-DEVELOPMENT OF NANOBODIES

26.09.2013

Ablynx [Euronext Brussels: ABLX] and Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, today announced that they have further expanded their relationship through a multi-year research alliance that could lead to at least four co-discovery and co-development collaborations. read more

Join E-news

Interested in a regular update of the life sciences and biotech sector in Flanders? Subscribe to our newsletter.

Subscribe now

Back to top

Print